延长肺保护性通气对COVID-19 ARDS患者肺恢复的影响:一项II期随机对照试验
该单中心随机对照试验纳入76例中重度COVID-19 ARDS且呼吸系统顺应性(CRS)<0.6(mL/Kg)/cmH2O的患者,干预组接受电阻抗断层成像指导的以最小化驱动压(ΔP)和患者通气驱动力为目标的通气策略,对照组接受ARDSNet低PEEP策略。主要终点为改良肺损伤评分(mLIS,整合每日CRS、氧需求、氧合和X线,至第28天),结果显示两组平均mLIS无差异(P=0.95)。干预组mLIS改善更快(达到最大改善63%的时间1.4天 vs 7.2天,P<0.001),CRS持续改善至第28天(P=0.009),随机化至呼吸室内空气时间更短(P=0.02),但28天生存率和脱机时间无差异。研究因疫情消退连续三个月无入组而提前终止。
要点
- 干预组mLIS达到最大改善63%的时间为1.4天,对照组为7.2天(P<0.001),提示肺损伤评分改善更快。
- 干预组呼吸系统顺应性(CRS)持续改善至第28天(P=0.009)。
- 干预组随机化至呼吸室内空气时间更短(P=0.02),但28天生存率和脱机时间两组无差异。
- 主要终点至第28天平均mLIS两组无差异(P=0.95)。
- 研究因疫情消退连续三个月无入组而提前终止,作者认为该策略可行,并建议在更大规模试验中进一步验证。
适用人群与场景
- 中重度COVID-19 ARDS患者,呼吸系统顺应性(CRS)<0.6(mL/Kg)/cmH2O。
诊断标准与关键阈值
- 纳入标准:中重度COVID-19 ARDS且CRS<0.6(mL/Kg)/cmH2O。
处置流程与药物剂量
- 干预组:接受电阻抗断层成像指导的通气策略,目标为最小化驱动压(ΔP)和患者通气驱动力,并包含逐步控制患者通气驱动力的方案。
- 对照组:接受ARDSNet低PEEP策略。
- 主要终点mLIS整合每日CRS、氧需求、氧合和X线测量至第28天,并按生存和拔管率进行分层调整。
研究设计与关键结果
- 单中心随机对照试验,意向性治疗分析纳入76例患者,其中37例随机分配至干预组。
- 研究因疫情消退连续三个月无患者入组而提前终止。
- 主要终点:至第28天平均mLIS两组无差异(P=0.95)。
- 干预组mLIS改善更快:达到最大改善63%的时间为1.4天 vs 对照组7.2天(P<0.001),由氧合和X线持续改善驱动(P=0.001)。
- 干预组呼吸系统顺应性(CRS)持续改善至第28天(P=0.009)。
- 干预组随机化至呼吸室内空气时间更短(P=0.02)。
- 28天生存率和脱机时间两组无差异。
证据类型、等级与局限
- 证据类型:II期随机对照试验。
- 局限:研究因疫情消退连续三个月无入组而提前终止;作者认为有希望的次要结局提示肺恢复更快,支持在更大规模试验中进一步验证该策略。
对床旁实践的改变
- 作者认为,实施个体化PEEP策略联合延长肺保护是可行的。
- 作者认为,有希望的次要结局提示肺恢复更快,支持在更大规模试验中进一步验证该策略。
指南或共识出处
- ClinicalTrials.gov注册号NCT04497454,注册日期2020年8月4日。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Protective ventilation seems crucial during early Acute Respiratory Distress Syndrome (ARDS), but the optimal duration of lung protection remains undefined. High driving pressures (ΔP) and excessive patient ventilatory drive may hinder lung recovery, resulting in self-inflicted lung injury. The hidden nature of the ΔP generated by patient effort complicates the situation further. Our study aimed to assess the feasibility of an extended lung protection strategy that includes a stepwise protocol to control the patient ventilatory drive, assessing its impact on lung recovery.
METHODS: We conducted a single-center randomized study on patients with moderate/severe COVID-19-ARDS with low respiratory system compliance (CRS < 0.6 (mL/Kg)/cmH2O). The intervention group received a ventilation strategy guided by Electrical Impedance Tomography aimed at minimizing ΔP and patient ventilatory drive. The control group received the ARDSNet low-PEEP strategy. The primary outcome was the modified lung injury score (mLIS), a composite measure that integrated daily measurements of CRS, along with oxygen requirements, oxygenation, and X-rays up to day 28. The mLIS score was also hierarchically adjusted for survival and extubation rates.
RESULTS: The study ended prematurely after three consecutive months without patient enrollment, attributed to the pandemic subsiding. The intention-to-treat analysis included 76 patients, with 37 randomized to the intervention group. The average mLIS score up to 28 days was not different between groups (P = 0.95, primary outcome). However, the intervention group showed a faster improvement in the mLIS (1.4 vs. 7.2 days to reach 63% of maximum improvement; P < 0.001), driven by oxygenation and sustained improvement of X-ray (P = 0.001). The intervention group demonstrated a sustained increase in CRS up to day 28 (P = 0.009) and also experienced a shorter time from randomization to room-air breathing (P = 0.02). Survival at 28 days and time until liberation from the ventilator were not different between groups.
CONCLUSIONS: The implementation of an individualized PEEP strategy alongside extended lung protection appears viable. Promising secondary outcomes suggested a faster lung recovery, endorsing further examination of this strategy in a larger trial. Clinical trial registration This trial was registered with ClinicalTrials.gov (number NCT04497454) on August 04, 2020.
参考来源
- Costa ELV, Alcala GC, Tucci MR, et al. Impact of extended lung protection during mechanical ventilation on lung recovery in patients with COVID-19 ARDS: a phase II randomized controlled trial. Ann Intensive Care. 2024. PMID: 38849605. doi:10.1186/s13613-024-01297-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。